imipenem/cilastatin actavis
teva b.v. - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
imipenem/cilastatin sun
sun pharmaceutical industries europe b. v. - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
imipenem/cilastatin venus pharma
venus pharma gmbh - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
imipenem/cilastatin atb
adeofarma, uab - imipenemas/cilastatinas - milteliai injekciniam ar infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
imipenem/cilastatin eberth
niromed, uab - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
imipenem e cilastatina hikma
edupharma, uab - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
tienam i.v.
merck sharp & dohme, uab - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
recarbrio
merck sharp & dohme b.v. - imipenem monohidratas, cilastatin natrio, relebactam monohidratas - gram-neigiamų bakterijų infekcijos - carbapenems, antibacterials for systemic use, - recarbrio is indicated for:- treatment of hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap), in adults (see sections 4. 4 ir 5. - treatment of bacteraemia that occurs in association with, or is suspected to be associated with hap or vap, in adults. - treatment of infections due to aerobic gram-negative organisms in adults with limited treatment options (see sections 4. 2, 4. 4 ir 5. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.
nimedine
lex ano, uab - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin
nimedine
corpus medica, uab - imipenemas/cilastatinas - milteliai infuziniam tirpalui - 500 mg/500 mg - imipenem and cilastatin